Humira's approval widened to include ulcerative colitis

Humira's approval widened to include ulcerative colitis
(HealthDay)—Humira (adalimumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe ulcerative colitis in adults, the agency said Friday.

Humira—an anti- agent that's designed to suppress abnormal inflammatory and immune responses—has already been approved to treat a host of conditions, including , Crohn's disease, and plaque psoriasis.

Ulcerative colitis affects about 620,000 people in the United States, according to the U.S. National Institutes of Health.

The most common side effects of Humira include infection, injection-site reaction, headache, and rash, according to an FDA news release.

The drug is manufactured by Abbott Laboratories, based in North Chicago, Ill.


Explore further

Study identifies potential new class of drug for treating ulcerative colitis

More information: The U.S. National Library of Medicine has more about ulcerative colitis.

Copyright © 2012 HealthDay. All rights reserved.

Citation: Humira's approval widened to include ulcerative colitis (2012, October 1) retrieved 26 May 2019 from https://medicalxpress.com/news/2012-10-humira-widened-ulcerative-colitis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more